Shares of Theravance Inc. (NASDAQ: THRX) rallied on Monday after a report from the U.S. drug regulators showed that the once-a-day lung disease treatment Breo Ellipta, which the company is developing in conjunction with the GlaxoSmithKline Plc, might get an approval.
[...]
Recent Comments